ASCO Genitourinary Symposium

Cabometyx Before Surgery May Shrink Tumors With No Disease Progression in Advanced Kidney Cancer

February 22nd 2022, 8:00pm

Article

Treatment with Cabometyx before surgery in patients with advanced renal cell carcinoma, a type of kidney cancer, may provide benefits, although further research is required before a decision is made about its role in presurgical treatment.

Updated Results on Lenvima-Keytruda Combo ‘Still Encouraging’ for Patients With Advanced Kidney Cancer, Expert Says

February 22nd 2022, 4:41pm

Article

Although the data failed to identify a predictive biomarker in patients with advanced kidney cancer, an expert from Memorial Sloan Kettering Cancer Center in New York notes that the results indicate that no one should be excluded from receiving Lenvima plus Keytruda.

Immunotherapy Agent Misses Study Survival Goal in Advanced Penile Cancer

February 22nd 2022, 2:08pm

Article

Tecentriq failed to meet the progression-free survival goal in a trial analyzing the immunotherapy agent in advanced squamous cell carcinoma of the penis.

Even in the Prescence of Health Complications and Other Medications, Nubeqa Maintains Safety, Efficacy in Prostate Cancer Treatment

February 21st 2022, 8:00pm

Article

Patients with nonmetastatic castration-resistant prostate cancer who were taking other medications or had health complications still derived a survival benefit from treatment with Nubeqa, research showed.

Fotivda Boosts Survival and Has ‘Interesting’ – and Tolerable – Safety Profile for Kidney Cancer Treatment

February 21st 2022, 4:00pm

Article

Fotivda – a TKI drug that was approved last year – not only improved survival outcomes, but was also very tolerable in terms of side effects for patients with metastatic renal cell carcinoma.

Immunotherapy Combinations Offer ‘Hope and Promise’ for Patients with Advanced Renal Cell Carcinoma

February 23rd 2021, 2:00pm

Video

Positive results from the phase 3 CLEAR clinical trial, presented at the 2021 ASCO Genitourinary Cancers Symposium, are just one more dataset that could offer “a sense of hope and promise” for patients with advanced renal cell carcinoma (RCC), says the study’s lead author, Dr. Robert J. Motzer.

Cabometyx Significantly Prolongs Survival Over Sutent in Rare Form of Kidney Cancer

February 18th 2021, 2:00pm

Article

The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.

Padcev Continues to Show Promise in Patients with Previously Treated Bladder Cancer

February 15th 2021, 10:00pm

Article

Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.

Lenvima Plus Keytruda Associated With Better Results Than Sutent Alone in Patients With Advanced Type of Kidney Cancer

February 13th 2021, 10:00pm

Article

The results of the phase 3 trial, according to one expert, support the use of Lenvima with Keytruda as a possible first-line treatment option for patients with advanced renal cell carcinoma.

Novel Therapy Demonstrates Limited Activity and Poor Safety Outcomes in Patients With Metastatic Renal Cell Carcinoma

February 13th 2021, 6:00pm

Article

Treatment with sapanisertib was associated with limited activity and poor safety outcomes in patients with refractory metastatic renal cell carcinoma.